Neurolixis Inc. offers a warm welcome to Violettte Richin, MSc, as research associate. Ms Richin trained as a pharmacist at the University of Lyon, France, with a particular interest in neuroscience and brain imaging. She joins Neurolixis in the context of a collaboration with the Lyon Neuroscience Research center (CRNL) in the team led by Prof. Luc ZIMMER where she will develop new brain imaging tools to investigate the activity of Neurolixis drug candidates, notably novel antidepressant compounds such as NLX-204. Ms Richin is registered with the doctoral training school at the University of Lyon under a ‘CIFRE’ funding scheme and will be co-supervised by Dr. Wael Zeinyeh at CRNL and Adrian Newman-Tancredi at Neurolixis.

See more information concerning Neurolixis' team.

LinkedIn profile of Violette RICHIN.

Neurolixis CEO, Adrian Newman-Tancredi, PhD, DSc, was interviewed by the regional business accelerator of Castres-Mazamet, in southern France, which has been supporting the company since 2014. Adrian outlined his background in neuroscience research, starting with doctoral research in the UK, before moving to industrial pharmaceutical research at Servier, Pierre Fabre and now Neurolixis. A recent highlight is the launch of a clinical trial on NLX-112 for treatment of dyskinesia in Parkinson's disease, the fruit of a decade of work on movement disorders (see previous press release). 
See full interview (in French) here.



A new Neurolixis method-of-use patent has issued in the USA, expanding protection of NLX-112 for treatment of movement disorders. Specifically, the patent covers the use of NLX-112 to treat side-effects induced by tetrabenazine (a drug that targets brain vesicular monoamine transporters, VMAT) in patients suffering from hyperkinetic disorders such as Huntington’s disease. Tetrabenazine reduces the hyperkinesia, also known as chorea, but has a high incidence of depression and parkinsonism side-effects. In animal models, NLX-112 and related compounds reversed both of these side effects of tetrabenazine, suggesting that it could improve management of Huntington's disease and, potentially, other hyperkinetic disorders.
See full patent here:

NLX-112 is currently undergoing a Phase 2A clinical trial for treatment of L-DOPA-induced dyskinesia in Parkinson’s disease (see previous press release).